A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.

NCT01033396 Phase 2 COMPLETED

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	64
Start date	2010-01
Completion	2010-05

Conditions

• Allergic Rhinitis

Interventions

• PF-03654764
• Allegra
• PF-03654764
• Allegra-D
• Placebo

Primary outcomes

• Congestion scores — 6 hours
• Other allergic rhinitis symptoms — 6 hours

Countries

Canada